Table 2 |
|||||
|
RT-PCR of 21 cytokine genes expressed as Delta Ct value and stratified by LN |
|||||
|
n (%) of positive patients |
All n = 46 |
LN+ n = 20 (43.5%) |
LN- n = 26 (52.4%) |
Wilcoxon P value |
|
|
|
|||||
|
CCR7 |
45 (98%) |
8 (-10; -7) |
-8 (-9; -7) |
-8 (-10; -7) |
0.465 |
|
IFN-γ |
35 (76%) |
-10 (-12; -9) |
-10 (-11; -9) |
-11 (-12; -8) |
0.656 |
|
IL-10 |
45 (98%) |
-7 (-8; -6) |
-7 (-8; -7) |
-7 (-8; -6) |
0.312 |
|
IL-12A |
41 (89%) |
-9 (-10; -8) |
-9 (-10; -8) |
-10 (-11; -8) |
0.188 |
|
IL-13 |
11 (24%) |
-14 (-15; -13) |
-15 (-16; -15) |
-13 (-14; -11) |
0.109 |
|
IL-15 |
42 (91%) |
-9 (-9; -8) |
-8 (-9; -8) |
-9 (-10; -8) |
0.104 |
|
IL-17A |
15 (33%) |
-11 (-13; -9) |
-13 (-14; -11) |
-11 (-11; -9) |
0.121 |
|
IL-18 |
46 (100%) |
-6 (-7; -6) |
-7 (-7; -6) |
-6 (-7; -5) |
0.418 |
|
IL-1β |
43 (94%) |
-8 (-9; -7) |
-9 (-9; -8) |
-8 (-9; -7) |
0.517 |
|
IL-2 |
29 (59%) |
-12 (-14; -11) |
-13 (-14; -11) |
-12 (-14; -12) |
0.846 |
|
IL-21 |
20 (43%) |
-13 (-14; -12) |
-13 (-14; -12) |
-13 (-14; -12) |
0.909 |
|
IL-22 |
7 (15%) |
-12 (-14; -11) |
-13 (-15; -12) |
-11 (-13; -11) |
0.629 |
|
IL-23A |
45 (98%) |
-5 (-6; -5) |
-5 (-6; -4) |
-6 (-8; -5) |
0.058 |
|
IL-28A |
21 (46%) |
-10 (-12; -9) |
-10 (-12; -8) |
-11 (-11; -10) |
0.622 |
|
IL-33 |
41 (89%) |
-11 (-12; -9) |
-11 (-12; -9) |
-11 (-12; -9) |
0.646 |
|
IL-6 |
44 (96%) |
-8 (-10; -6) |
-8 (-9; -7) |
-8 (-10; -5) |
0.706 |
|
IL-7 |
44 (96%) |
-6 (-7; -6) |
-6 (-7; -5) |
-7 (-7; -6) |
0.608 |
|
IL-8 |
46 (100%) |
-4 (-6; -2) |
-4 (-5; -3) |
-3 (-6; -2) |
0.877 |
|
LTβ |
44 (96%) |
-6 (-8; -5) |
-6 (-7; -5) |
-6 (-8; -6) |
0.443 |
|
TGF-β1 |
46 (100%) |
-3 (-4; -2) |
-3 (-4; -3) |
-3 (-3; -2) |
0.050 |
|
TNF-α |
46 (100%) |
-7 (-8; -6) |
-7 (-8; -6) |
-7 (-8; -6) |
0.816 |
|
|
|||||
|
Celis et al. Arthritis Research & Therapy 2012 14:R93 doi:10.1186/ar3817 |
|||||
